JOMED to pay $205 million to buy distribution partner EndoSonics to break into US market
This article was originally published in Clinica
Executive Summary
Dutch company JOMED is to propel itself into the US market with its $205 million cash purchase of distribution and product development partner EndoSonics. Coronary stent producer JOMED is offering $11 a share, representing a premium of over 50% to the US company's closing price on the announcement.